Model-based approaches to increase efficiency of drug development in schizophrenia: A can't miss opportunity

Expert Opinion on Drug Discovery

Volumn 4, Issue 8, 2009, Pages 837-856

  Nucci, Gianluca ^b   Gomeni, Roberto ^a   Poggesi, Italo ^a  

^a GSK   (Italy)

^b PFIZER INC   (United States)

Author keywords

Dropout; Efficacy; Model based drug development; PK PD; Safety; Schizophrenia; Variability

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DEHYDROSERTINDOLE; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; ILOPERIDONE; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RACLOPRIDE C 11; RISPERIDONE; SERTINDOLE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOTEPINE;

AGITATION; AGRANULOCYTOSIS; ANXIETY; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DRUG DEVELOPMENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INSOMNIA; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MYOCARDITIS; NONHUMAN; OPTIMAL DRUG DOSE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; WEIGHT GAIN;

EID: 68149157300     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903036073     Document Type: Review

References (137)

1. Gomeni R, Bani M, D'Angeli C, et al. Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. Eur J Pharm Sci 2001;13(3):261-270 (Pubitemid 32522578)
2. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res 1992;9(6):826-833
3. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61(3):275-291 (Pubitemid 27145429)
4. Sheiner LB, Steimer J-L. Pharmacokinetic/ pharmacodynamic modeling in drug development. Ann Rev Pharmacol Toxicol 2000;40(1):67-95 (Pubitemid 30340674)
5. Lesko LJ, Rowland M, Peck CC, et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 2000;10:iv-xiv (Pubitemid 30317459)
6. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of Clinical Trials. Ann Rev Pharmacol Toxicol 2000;40(1):209-234
7. Zhang L, Sinha V, Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006;33(3):369-393 (Pubitemid 44020386)
8. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007;82(1):21-32
9. Gobburu JVS, Lesko LJ. Quantitative Disease, Drug, and Trial Models. Ann Rev Pharmacol Toxicol 2009;49(1):291-301
10. Available from: http://www.fda.gov/oc/ initiatives/criticalpath/ whitepaper.html Critical Path initiative. [Accessed 11 May 2009]
11. Available from: http://www.emea.europa. eu/pdfs/general/direct/ directory/3416303enF.pdf Paper "The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future". [Accessed 11 May 2009]
12. Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68(6):677-687 (Pubitemid 32059994)
13. Chabaud S, Girard P, Nony P, Boissel J-P. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokin Pharmacodyn 2002;29(4):339-363 (Pubitemid 35471655)
14. Frey N, Laveille C, Paraire M, et al. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 2002;55(2):147-157 (Pubitemid 36240273)
15. Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005;7(3):E513-22 (Pubitemid 41631737)
16. Kowalski KG, Olson S, Remmers AE, Hutmacher MM. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin Pharmacol Ther 2008;83(6):857-866 (Pubitemid 351704916)
17. Barrett JS, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov 2007;2(2):185-209 (Pubitemid 47073087)
18. Schmidt S, Schuck E, Kumar V, et al. Integration of pharmacokinetic/ pharmacodynamic modeling and simulation in the development of new anti-infective agents-minimum inhibitory concentration versus time-kill curves. Expert Opin Drug Discov 2007;2(6):849-860 (Pubitemid 47296527)
19. Ette EEI, Williams PJ, editors, Pharmacometrics. The science of quantitative pharmacology. 2007, John Wiley & Sons
20. Cutting J. Descriptive psychopathology. In: Hirsch SR, Weinberger DR, editors, Schizophrenia, Second Edition. Blackwell Science Ltd; 2003. p. 15-24
21. Bhugra D. The global prevalence of schizophrenia. PloS Med 2005;2(5):e151 doi:10.1371/journal.pmed.0020151
22. Castle D, Wesseley S, Der G, Murray RM. The incidence of operationally defined schizophrenia in Camberwell 1965-1984. Br J Psychiatry 1991;159(6):790-794
23. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Ann Rev Med 2007;58(1):49-61 (Pubitemid 46706500)
24. Norman RMG, Malla AK, Cortese L, Diaz F. study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Res 1996;19(1):73-85 (Pubitemid 26133215)
25. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, American Psychiatric Association (APA), 1994
26. Pierre JM. Deconstructing schizophrenia for DSM-V: challenges for clinical and research agendas. Clin Schizophr Relat Psychoses 2008;2(2):166-174
27. Van den Oord EJ, Rujescu D, Robles JR, et al. Factor structure and external validity of the PANSS revisited. Schizophr Res 2006;82(2-3):213-223 (Pubitemid 43290685)
28. Wadenberg M-LG, Kapur S, Soliman A, et al. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behaviour in rats. Psychopharmacol 2000;150(4):422-429 (Pubitemid 30470221)
29. Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003;305(2):625-631 (Pubitemid 36459179)
30. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull Advance access published Aug 2008, 22; doi:10.1093/schbul/sbn110 • Interesting meeting report on placebo effects in schizophrenia.
31. Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008;34(2):286-291 (Pubitemid 351323340)
32. Lieberman JA, Stroup S, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209- 1223 (Pubitemid 41345943)
33. Gudiksen M, Fleming E, Furstenthal L, Ma P. What drives success for specialty pharmaceuticals? Nat Rev Drug Discov 2008;7(7):563-567
34. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/ dopamine receptors. Nature 1976;261(5562): 717-719
35. Talbot PS, Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 2002;12(6):503-511 (Pubitemid 35408701)
36. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158(3):360-369 (Pubitemid 32205190)
37. Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 2008;22(8):882-894
38. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251(1):238-246 (Pubitemid 19261970)
39. Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry 2002;181(4):271-275
40. Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001;179(6):503-508 (Pubitemid 34031674)
41. Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 2008;584(2-3):318-327 •• Comprehensive PK-PD approach relating plasma concentrations of different antipsychotics with D2 receptor occupancy and CAR in rats, potentially useful for the prediction of the effective exposures in humans.
42. Parker TJ, Della Pasqua OE, Loizillon E, et al. Pharmacokinetic- pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats. British J Pharmacol 2001;132(1):151-158 (Pubitemid 32128444)
43. Deutsch SI, Rosse RB, Billingslea EN, et al. Topiramate antagonizes MK-801 in animal models of schizophrenia. Eur J Pharmacol 2002;449(1-2):121-125 (Pubitemid 34887999)
44. Nordquist RE, Risterucci C, Moreau JL, et al. Effect of aripiprazole/OCP-14597 on motor activity, pharmacology models of psychosis, and brain activity in rats. Neuropharmacol 2008;54(2):405-418
45. Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptor: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacol 2006;31(9):1854-1863 (Pubitemid 44246331)
46. Wong DF, Tauscher J, Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacol Rev 2009;34:187-203
47. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130(Pt 10):2616-2635 (Pubitemid 47511706)
48. McGuire PK, Matsumoto K. Functional neuroimaging in mental disorders. World Psychiatry 2004;3(1):6-11
49. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study in schizophrenic patients. Biol Psychiatry 1993;33(4):227-235 (Pubitemid 23091497)
50. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-293 (Pubitemid 29077120)
51. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156(6):869-875 (Pubitemid 29260341)
52. Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001;11(2):105-110
53. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161(5):818-825 (Pubitemid 38625334)
54. Takano A, Suhara T, Ikoma Y, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 2004;7(1):19-26 (Pubitemid 38523803)
55. Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacol 2006;31(5):1027-1035
56. Mamo D, Kapur S, Keshavan M, et al. D2 Receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacol 2008;33(2):298-304 (Pubitemid 350243350)
57. Zamuner S, Gomeni R, Bye A. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. Nucl Med Biol 2002;29(1):115-123 (Pubitemid 34088167)
58. Zamuner S, Gomeni R. Optimal design to estimate the time varying receptor occupancy relationship in a PET experiment. Abstracts of the XVI Annual Meeting of the Population Approach Group in Europe [abstract 1099]. Copenhagen, Danemark, 13-15 June, 2007. 16 [www.page- meeting.org/?abstract = 1099]
59. Lim KS, Kwon JS, Jang I-J, et al. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther 2007;81(2):252-258 • To our knowledge, the first published example in which a population PK-PD model was applied to D2 receptor occupancy data.
60. Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]-IBZM SPECT and [11C]-Raclopride PET. Neuroimage. Corrected Proof, Available online 20 February 2009; accessed 12 March 2009.
61. Key SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr Bull 1987;13:261-276 (Pubitemid 18039085)
62. Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol Rep 1962;10:799-812
63. Guy W, editor. ECDEU Assessment manual for Psychopharmacology. 1976, Rockville, MD, U.S. Department of Health, Education, and Welfare
64. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24(2):192-208
65. Centorrino F, Baldessarrini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of cronically psychotic patients. J Clin Psychopharmacol 1994;14(2):119-125 (Pubitemid 24120710)
66. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl B):133-136 (Pubitemid 24353037)
67. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl B):117-121 (Pubitemid 24353033)
68. Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2004;11(3):279-296 • An interesting general review on the characteristics of atypical antipsychotics. (Pubitemid 38240208)
69. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46(5):359-388 • A comprehensive review of the plasma concentrations of therapeutic interest for atypical antipsychotics.
70. Odou P, Levron JC, Luyckx M, et al. Risperidone drug monitoring. A useful clinical tool? Clin Drug Invest 2000;19(4):283-292
71. Mauri MC, Laini V, Boscati L, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001;16(1):57-63 (Pubitemid 32171333)
72. Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006;20(1):86-90
73. Rowland M. Bioavailability assessment and pharmacologic response: Impact of first-pass loss when both drug and metabolites are active. J Pharmacokinet Biopharm 1988;16(6):573-593 (Pubitemid 19034766)
74. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacol 1994;114(4):566-572 (Pubitemid 24152136)
75. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenics. J Clin Psychopharmacol 1997;17(6):472-477 (Pubitemid 28389187)
76. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001;21(1):14-20 (Pubitemid 32096745)
77. Fellows L, Ahmad F, Castle DJ, et al. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit 2003;25(6):682-689 (Pubitemid 37499302)
78. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005;20(1):55-60 (Pubitemid 40092392)
79. Available from: http://www.fda.gov/cder/ foi/nda/2002/21-436-Abilify- biopharmr- P1.pdf [Accessed 11 May 2009]
80. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007;164(9):1411-1417 (Pubitemid 47461142)
81. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]-fallypride PET study. Am J Psychiatry 2008;165(8):988-995
82. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]-fallypride. Neuropsychopharmacology 2008;33(13):3111-3125
83. Kirschbaum KM, Müller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008;9(3):212-218
84. Baroldi P, Wolfgang C, Fisher D. A pharmacokinetic-pharmacodynamic relationship exists for efficacy of iloperidone, a novel investigational antipsychotic agent. 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA, 19-24 May 2007
85. Available from: http://www.fda.gov/cder/ foi/nda/2006/ 021999s000-ClinPharmR- Part1.pdf [Accessed 11 May 2009]
86. Available from: http://www.fda.gov/cder/ foi/nda/2006/021999s000- ClinPharmR- Part2.pdf [Accessed 11 May 2009]
87. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002;63(11):992-997 (Pubitemid 35388057)
88. Martin JLR, Pérez V, Sacristán M, et al. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006;21(1):11-20 (Pubitemid 43243048)
89. Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008;34(2):286-291 (Pubitemid 351323340)
90. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003;30(1):83-103 (Pubitemid 36571070)
91. Gomeni R, Lavergne A, Merlo-pich E. Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J Pharm Sci 2009;36(1):4-10
92. Kimko HC, Reele SSB, Holford NHG, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000;68(5):568-577 •• To our knowledge, the first published example of clinical trial simulation in the schizophrenia indication.
93. Gomeni R, Merlo-Pich E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 2007;63(5):595-613 (Pubitemid 46632577)
94. Piotrovsky V. Indirect-response model for the analysis of concentration-effect relationships in clinical trials where response variables are scores [abstract 773]. Abstracts of the XIV Annual Meeting of the Population Approach Group in Europe. Pamplona, Spain, 16 - 17 June, 2005. 14[www.page-meeting.org/?abstract = 773] •• Interesting 'full blown' PK-PD approach for modeling the clinical effect of antipsychotics.
95. Ortega Azpitarte I, Vermeulen A, Piotrovsky V. Concentration-response analysis of antipsychotic drug effects using an indirect response model [abstract 995]. Abstracts of the XV Annual Meeting of the Population Approach Group in Europe. Brugge/Bruges, Belgium, 14- 16 June, 2006. p. 15 [www.page-meeting.org/?abstract = 995] •• Interesting 'full blown' PK-PD approach for modeling the clinical effect of antipsychotics.
96. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia. Clin Pharmacol Ther. Corrected proof. Available on line 22 Apr 2009. dx.doi.org/10.1038/clpt.2009.44 •• Interesting 'full blown' PK-PD approach for modeling the clinical effect of antipsychotics and the time course of dropouts.
97. de Greef R, Friberg LE, Chapel S, et al. Modeling and simulation to integrate efficacy and safety data following full development: a case study in schizophrenia and bipolar disorder [abstract 1274]. Abstracts of the XVII Annual Meeting of the Population Approach Group in Europe. Marseille, France, 18-20 June, 2008. 17 [www.page-meeting.org/?abstract = 1274]
98. Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapiramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 2005;20(3):187-199 •• Interesting PK-PD model for antipsychotics-induced EPS effects based on receptor occupancy theory.
99. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy analysis of the contribution of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(3):368-378 •• Interesting PK-PD model for antipsychotics-induced metabolic effects based on receptor occupancy theory.
100. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
101. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008;22(2 Suppl):46-55
102. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 1995;274(2):921-927 • Interesting PK-PD model for describing the antipsychotics-induced effects on prolactin.
103. Ma G, Friberg LE, Karlsson MO. Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin. Abstracts of the XVII Annual Meeting of the Population Approach Group in Europe [abstract 1299]. Marseille, France, 18-20 June, 2008. 17[www.page-meeting. org/?abstract = 1299] • Interesting PK-PD model for describing the antipsychotics-induced effects on prolactin.
104. Friberg LE, Vermeulen AM, Karlsson MO. A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment. Abstracts of the XV Annual Meeting of the Population Approach Group in Europe [abstract 940]. Brugge/Bruges, Belgium, 14-16 June, 2006. 15[www.page-meeting. org/?abstract = 1299]
105. Friberg LE, Vermeulen AM, Petersson KJF, Karlsson MO. An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 2009;85(4):409-417 •• Interesting PK-PD model for describing the antipsychotics-induced effects on prolactin.
106. Gabriellsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concept and applications. 3rd edition. Swedish Pharmaceutical Press, 2000. p. 231-251
107. Bagli M, Suverkrup R, Quadflieg R, et al. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 1999;291(2):547-554 (Pubitemid 29503523)
108. de Visser SJ, van der Post J, Pieters MSM, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001;51(2):119-132 (Pubitemid 32219735)
109. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159(1):133-135
110. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-1134 (Pubitemid 34920235)
111. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Res 2003;58:32-45 (Pubitemid 36351620)
112. Piotrovsky V. Pharmacokineticpharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005;7(3):E609-24 (Pubitemid 41631729)
113. Shin JG, Kang WK, Shon JH, et al. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol 2007;63(2):206-215
114. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-716
115. Goss SL, Ouellet D. Dose and time-response modeling of the effects of marketed products used in treatment of schizophrenia [abstract PII-09]. 2009 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, Maryland March 18-21, 2009. Clin Pharmacol Ther 2009;85(Suppl 1):S40
116. Ahadieh S, Corrigan B, Riley S, Lalonde R. Model based meta analysis of positive and negative syndrome scale (PANSS) in schizophrenic patients [abstract PII-89]. 2009 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, Maryland March 18-21, 2009. Clin Pharmacol Ther 2009;85(Suppl 1):S64
117. Nordström AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152(10):1444-1449
118. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001;158(2):311-314 (Pubitemid 32116532)
119. Farde L, Nordström AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
120. Talvik M, Nordström AL, Nyberg S, et al. No support for regional selectivity in clozapine-treated patients: a PET study with [11C]raclopride and [11C]FLB 457. Am J Psychiatry 2001;158(6):926-930
121. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152(2):173-178
122. Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res Neuroimaging 1996;67(3):163-171
123. Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berlin) 1997;131(2):148-152 (Pubitemid 27261602)
124. Fitzgerald PB, Kapur S, Remington G, et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berlin) 2000;149(1):1-5 (Pubitemid 30187359)
125. Reimold M, Solbach C, Noda S, et al. Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berlin) 2007;190(2):241-249
126. Tauscher J, Jones C, Remington G, et al. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7(3):317-321 (Pubitemid 34280640)
127. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berlin) 2008;197(2):229-235
128. Gefvert O, Bergström M, Långström B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berlin) 1998;135(2):119-126 (Pubitemid 28055494)
129. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57(6):553-559 (Pubitemid 30349435)
130. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69(1):81-86 (Pubitemid 351282000)
131. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005;8(1):27-36 (Pubitemid 40388811)
132. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006;163(3):396-401 (Pubitemid 44469380)
133. Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry 2008;69(8):1281-1286
134. Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009;17(3):255-263
135. Uchida H, Graff-Guerrero A, Mulsant BH, et al. Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. Schizophr Res. In Press, Corrected Proof, Available online 28 January 2009, accessed 17 March 2009. doi:10.1016/j.schres.2008.12.022
136. Nyberg S, Olsson H, Nilsson U, et al. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berlin) 2002;162(1):37-41 (Pubitemid 34639554)
137. Baldessarini RJ, Tarazi FI. Pharmacotherapy of Psychosis and Mania. In: Brunton LL, Parker KL, Murri N, Blumenthal DK, editors, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition (online). McGraw-Hill